Clinical Trials

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy


Study ID
Boston BioMedical BBI-DSP7888-201G

NCT Number
NCT03149003 (Click on the NCT number for more information about the trial)

Research Study Number
2017-0363

Principle Investigator
Dr. Samuel Goldlust

Phase
II

Sponsor
Boston BioMedical


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now